Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 3 of 4
Archive
Proactive news round-up: ValiRx, ITM Power, Tharisa ...
A glance at some of the stories on the Proactive newswire today.
Malvern top of the class after tie-up with Singaporean tech group
Some of the main news-driven share price changes at 3.15pm
ValiRx prostate cancer drug delivers eye-catching early results
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
FTSE 100 hits 10th successive record high close
FTSE 100 shares appear positively related to the Nasdaq as the London ticker again hits a fresh record high on Wednesday - its tenth successive
Archive
Proactive news round-up: Windar Photonics, Mkango Resources, San Leon Energy …
A glance at some of the stories on the Proactive newswire today
Yorkville converts loan notes into ValiRx shares
The notes were converted at 5.625p a share, versus a current share price of 5.15p..
Archive
Proactive News round-up: Service Power, Green Dragon Gas, Plexus ....
A glance at today's headlines on the Proactive newswire ...
Archive
Proactive news round-up: Akers Biosciences, Base Resources, Rambler Metals...
A glance at some of the main stories on the Proactive newswire today
Archive
Proactive news round-up: Sound Energy, Matals Exploration, Acal ...
A snapshot of the stories on the Proactive newswire today
ValiRx's lead candidate study to be expanded
The trial is a phase I/II dose escalation study to assess safety and tolerability
Proactive news summary: Sirius Minerals stands out on big day for funding
Also covered: Blur, Eckoh, Eurasia, FairFX, H&T, Rosslyn, KrisEnergy, Sierra Rutile, Tern, ValiRx, Xtract Resources
ValiRx encouraged by progress in lung cancer trial
Members of the ValiSeek joint venture made a site visit to the clinic in Tbilisi, Georgia
Funding boost for Sirius Minerals and 88 Energy, but its GAME OVER for Xcite
Suddenly there’s cash swilling around the AIM natural resources sector, but the return of positive sentiment is too little too late for Xcite Energy.
ValiRx receives new patents in Japan and US for lead compounds
The patents relate to the firm's compounds VAL201 and VAL401, which are currently in clinical trials
ValiRx's recent data well received
The company has two drugs in clinical trials, VAL 201 for prostate cancer, and VAL 401 for non-small cell lung cancer
ValiRx reformulates key drug as endometriosis treatment
The company has two drugs in clinical trials, VAL 201 for prostate cancer, and VAL 401 for non-small cell lung cancer
Proactive news highlights: ATTRAQT, Lombard Risk, Rare Earth, TyraTech and more...
European Wealth Grouphas acquired CIMCO Partners Management Limited, ATTRAQT Group reports a boost to sales, and Westminster Group's ferry heads off on its maiden voyage.
ValiRx’s lead compound continues to perform well
“Studies continue to show preliminary indications of VAL201 positively effecting subjects' disease profile”
Risers & Fallers: Aldermore, ASA Resource, Iofona, Petro Matad, Polemos, Vast Resources
Paternoster Resources has taken a big stake in Polemos, which has done wonders for the latter's share price, but not Paternoster's
Green-light received for start of ValiRx's lung cancer trial
All approvals have now been granted for the trial, which will be carried out in Tbilisi, Georgia
Proactive news highlights: 88 Energy, Caledonia Mining, FairFX, Minds + Machines and more...
Sareum Holdings plays down a recent report, Eurasia Mining agrees a refining contract and Minds + Machines is seeing exceptional growth.
ValiRx receives notification of patent grant allowance in New Zealand for VAL401
ValiSeek Limited, the joint venture between ValiRx and Tangent Reprofiling Limited has received notification of a New Zealand patent grant allowance.
Risers & fallers: Victoria, Management Resources Solutions, OptiBiotix Health, Orogen Gold, Clear Leisure, Man Group
Carpet seller Victoria's results caught the eye, with revenue and adjusted EBITDA double what they were in the previous year
ValiRx suspends use of loan facility with Bracknor
Having sold off its Finnish subsidiary earlier this month for €800,000 in cash, ValiRx has now terminated its convertible loan note facility with Bracknor.
ValiRx receives important sign-off for cancer trial
The AIM-listed company, which is working with Tangent Reprofiling, said it had received a positive opinion recommending the trial protocol.
Proactive news highlights: Bacanora, Leni Gas Cuba, Metal Tiger, Westminster Group and more...
Leni Gas Cub shareholders unanimously approve reverse take-over bid, StratMin Global Resources enters into a conditional sale and purchase agreement with Bass Metals and progress at Rare EarthSonora lithium project in Mexico is going well.
ValiRx's sale of Finnish subsidiary will free up resources
The group will retain the licence to use TRAC technology (transcript analysis with the aid of affinity capture) in its development of therapeutic candidates.
FTSE 100 Index rises as Herencia gets in the money
Chilean copper miner did financing deals with two shareholders
FTSE100 heads north; Iofina bolsters small caps
FTSE AIM 100 was up 0.26% to 3,512, while the FTSE AIM All share gained 0.26% to stand at 745.290
ValiRx starts preparations for efficacy trial of cancer drug
ValiRx has also started preparatory work on a full efficacy study (phase III) of the drug in prostate cancer treatment.
Proactive new highlights: Amur Minerals, Fox Marble, Optibiotix, Sirius Minerals and more...
Amur Minerals has pitched the potential of its Kun-Manie nickel project in Far East Russia to potential investors in Korea.
Pharma small-caps get shot in arm from antibiotic report
Pharma company shares rise as report urges action to develop super-bug treatments
ValiRx advancing both lead compounds
A highlight of the year gone was Phase l/ll clinical trial of VAL201, which confirmed the compound was well tolerated and shown a high degree of safety.
Risers and Fallers: Pipehawk, Formation Group, Mobile Streams Risers...
Major share price risers and fallers in London at 3.30pm
FTSE 100 tumbles but Aim stocks make progress
People who measure such things say the chances of a rate hike in June have risen above 30%
ValiRx PLC readies for phase II clinical trial of lead cancer drug
The study will assess efficacy, safety and tolerability in people with the non-small cell variant of the disease where at least one form of chemotherapy has failed.
ValiRx making progress on several fronts
Life sciences firm ValiRx has been making progress on its lead drugs...
Proactive news highlights: ANGLE, Eland Oil & Gas, Fastjet, Obtala, Tekcapital and more...
Fastjet agrees to early lease termination, ANGLE's cancer detection device takes off and Obtala agrees to full settlement.
Risers & Fallers: Petro Matad, Avocet Mining, ASA Resources...
Major share price risers and fallers in London at 4.00pm
ValiRx joint venture awarded second US patent
The drug is targeting non-small-cell lung adenocarcinoma, the most common form of the disease.
Risers and fallers: Harvest Minerals, Norcon, Watchstone Group...
Image Scan's losses slashed. Cloudbuy rises on contract win. Kolar Gold's new broker raises fears of impending share issue.
ValiRx PLC to present at leading US cancer conference
The American Association for Cancer Research Annual Conference will take place in New Orleans, starting April 16.
UK stocks becalmed
Petroleum plays Bankers Petroleum and Bahamas Petroleum were the highlights of the small-caps scene
Risers and Fallers: Bankers Petroleum PLC, ANGLE PLC, PetroNeft Resources PLC..
Major share price risers and fallers in London at 4.15pm
ValiRx PLC tees up £4mln through convertible issue
The agreement will see Bracknor subscribe for the convertible loan notes in eight equal tranches of £0.5mln
Archive
Proactive news summary: Allergy Therapeutics PLC, Eurasia Mining PLC, Metal Tiger PLC and more...
Sirius Minerals' "world class" North Yorkshire project, update on Aureus and Allergy Therapeutics to lose finance director.
Stocks remain in doldrums as BoE stands pat
The Bank of England kept interest rates unchanged for the 84th month in a row.
FTSE100 rallies post Budget but small caps lower
Small cap shares were heading south in contrast to bigger brother FTSE100 but tech group Sopheon PLC was a notable riser.
ValiRx PLC targets US institutions with new appointment
Burns McClellan has already carried out an institutional investor introductory project for ValiRx.
ValiRx raises £500,000 to progess cancer trial
ValiRx has one drug, VAL201, going through phase I/II trials
Risers & Fallers: Digital Globe, Environmental Recycling, Imaginatik, UJ Oil ..
Below are the main news-driven share price changes at 1.00pm.
Archive
Proactive news summary: Westminster, ValiRx, NetScientific, Sound Energy and more...
Specialist security group Westminster saw shares advance as cargo screening operations began at Freetown International Airport (FNA) in Sierra Leone, West Africa.
Risers & Fallers: Next, Tern and Reckitt Benckiser...
Those of you who dumped shares of cyber-security group Sophos ahead of today's trading update: good call!
ValiRx looks at broadening lead drug to fertility problem
VAL201 is currently going through a phase I/II trial for prostate cancer treatment.
Archive
Proactive news summary: 88 Energy, accesso, Active Energy, Aminex, Atlantis Res, blur, Fox Marble...
Highlights of the news developments from the growth companies universe
ValiRx to expand prostate cancer trial after dose escalation
Next steps will be a trial expansion phase, which will include centres in addition to UCH in London.
Archive
Proactive news summary, including Alliance Pharma, Planet Payment, OPG Power Ventures and Redx Pharma
There were some fireworks at Proactive today... Alliance Pharma shares nudged higher on Thursday after it emerged it will receive £6.7mln in compensation.....
ValiRx sets up in Boston to strengthen investor base
New office will also position it in close proximity to the biggest biotech market in the world.
ValiRx to collaborate on gene silencing tech
Under the agreement, Pharmatest will design GeneICE constructs and test them in cancer model systems.
Investments and investor services
Proactive news highlights including AFC Energy, ValiRx, ITM Power, Ebiquity, Amur Minerals...
Shares in Atlantic Coal flew higher today but Ortac Resources took the top spot on the risers board.
ValiRx extends lymphoma biomarker patent protection to Japan
ValiRx said the biomarkers separate types of B-cell lymphomas into different prognostic groups.
ValiRx well placed to keep growth going
Its lead compound, VAL201, has passed safety controls and is showing early indications of efficacy even at low dosage.
ValiRx arranges £2.45mln finance for development work
The proceeds will help fund the drug developer’s therapeutic, biomarker and intellectual property developments.
Risers & Fallers: SABMiller, Styles & Wood, Dillistone, Cello Group, Synairgen and Quadrise Fuels
Below are the main news-driven share price movements at 12.30pm.
Investments and investor services
Most followed: Aviva, RSA Insurance, Shell, Sound Oil, Super Thursday, ValiRx, Zurich Insurance
Bank of England governor Mark Carney hopes the adoption of Three-In-One will oil the decision making process.
ValiRx signs collaboration deal with Leeds University
Professor Taylor has recently moved to the University of Leeds where helped develop VAL401, one of ValiRx's lead products.
Archive
FTSE100 heads lower as market runs out of positives
Britain's top share index closed almost 20 points lower...
Archive
Proactive news summary, including ValiRx, Mwana Africa, Versarien and Clinigen
Pharma and biotech stocks were prominent and ValiRx shares were boosted....
Investments and investor services
Risers & Fallers: blur Group, Arbuthnot, Admiral Group, Cable & Wireless, Atlas and more
blur Group attracted 30% more large business customers to its e-commerce platforms while Cable & Wireless reported flat first quarter mobile revenue.
ValiRx to up dosage in prostate cancer trial
"We are now nearing dose levels that we originally projected would be therapeutically significant.”
Archive
Proactive news summary, including Jubilee Platinum, Metal Tiger, Lydian International, Sound Oil and Strategic Minerals
Shares in Jubilee Platinum soared today on disposal news....
UPDATE - ValiRx to start clinical trial of lung cancer drug
The drug is being developed through a joint venture with Tangent Profiling.